Advertisement

Topics

[Articles] Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

20:52 EDT 30 Oct 2017 | The Lancet

CALM is the first study to show that timely escalation with an anti-tumour necrosis factor therapy on the basis of clinical symptoms combined with biomarkers in patients with early Crohn's disease results in better clinical and endoscopic outcomes than symptom-driven decisions alone. Future studies should assess the effects of such a strategy on long-term outcomes such as bowel damage, surgeries, hospital admissions, and disability.

Original Article: [Articles] Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

NEXT ARTICLE

More From BioPortfolio on "[Articles] Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...